β-blockers reduce bone resorption marker in early postmenopausal women

Annals of Human Biology

Volumn 32, Issue 6, 2005, Pages 738-745

  Pasco, Julie A ^a   Henry, Margaret J ^a   Nicholson, Geoffrey C ^a   Schneider, Hans G ^b   Kotowicz, Mark A ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b Alfred Pathology Service   (Australia)

Author keywords

blocker; Bone loss; Bone turnover markers; Ostmenopausal women; Population studies

Indexed keywords

BONE; CARDIOVASCULAR DISEASE; DISEASE TREATMENT; HORMONE; OBSERVATIONAL METHOD; PEPTIDE; WOMENS HEALTH;

ALKALINE PHOSPHATASE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; COLLAGEN; COLLAGEN TYPE 1; COLLAGEN TYPE I TRIMERIC CROSS LINKED PEPTIDE; COLLAGEN TYPE I TRIMERIC CROSS-LINKED PEPTIDE; PEPTIDE;

ARTICLE; BLOOD; DRUG EFFECT; ESTROGEN THERAPY; FEMALE; HUMAN; METABOLISM; MIDDLE AGED; OSTEOLYSIS; POSTMENOPAUSE;

ADRENERGIC BETA-ANTAGONISTS; ALKALINE PHOSPHATASE; BIOLOGICAL MARKERS; BONE RESORPTION; COLLAGEN; COLLAGEN TYPE I; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MIDDLE AGED; PEPTIDES; POSTMENOPAUSE;

EID: 33644863444     PISSN: 03014460     EISSN: 14645033     Source Type: Journal    
DOI: 10.1080/03014460500292168     Document Type: Article

References (24)

1. Ahlborg HG, Johnell O, Nilsson BE, Jeppsson S, Rannevik G, Karlsson MK. 2001. Bone loss in relation to menopause: A prospective study during 16 years. Bone 28:327-331.
2. Cherruau M, Facchinetti P, Baroukh B, Saffar JL. 1999. Chemical sympathectomy impairs bone resorption in rats: A role for the sympathetic system on bone metabolism. Bone 25:545-551.
3. Dalton M, Cameron AJ, Zimmet PZ, Shaw JE, Jolley D, Dunstan DW, Welborn TA; AusDiab Steering Committee. 2003. Waist circumference, waist-hip ratio and body mass index and their correlation with cardiovascular disease risk factors in Australian adults. J Intern Med 254:555-563.
4. Duda Jr RJ, O'Brien JF, Karzmann JA, Peterson JM, Mann KG, Riggs BL. 1988. Concurrent assays of circulating bone Gla-protein and bone alkaline phosphatase: Effects of sex, age, and metabolic bone disease. J Clin Endocrinol Metab 66:951-957.
5. Garnero P, Shih WJ, Gineyts E, Karpf DB, Delmas PD. 1994. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 79:1693-1700.
6. Garnero P, Sornay-Rendu E, Duboeuf F, Delmas PD. 1999. Markers of bone turnover predict postmenopausal forearm bone loss over 4 years: The OFELY Study. J Bone Miner Res 14:1614-1621.
7. Gutin B, Kasper MJ. 1992. Can vigorous exercise play a role in osteoporosis prevention? A review. Osteoporos Int 2:55-69.
8. Hansen MA, Overgaard K, Riis BJ, Christiansen C. 1991. Role of peak bone mass and bone loss in postmenopausal osteoporosis: 12 year study. BMJ 303:961-964.
9. Henry MJ, Pasco JA, Nicholson GC, Seeman E, Kotowicz MA. 2000. Prevalence of osteoporosis in Australian women: Geelong Osteoporosis Study. J Clin Densitom 3:261-268.
10. Khosla S, Atkinson EJ, Riggs BL, Melton 3rd LJ. 1996. Relationship between body composition and bone mass in women. J Bone Miner Res 11:857-863.
11. Kondo A, Togari A. 2003. In vivo stimulation of sympathetic nervous system modulates osteoblastic activity in mouse calvaria. Am J Physiol Endocrinol Metab 285:E661-E667.
12. Minkowitz B, Boskey A, Lane JM, Pearlman HS, Vigorita VJ. 1991. Effects of propranolol on bone metabolism in the rat. J Orthop Res 9:869-875.
13. Moore RE, Smith 2nd CK, Bailey CS, Voelkel EF, Tashjian Jr AH. 1993. Characterization of beta-adrenergic receptors on rat and human osteoblast-like cells and demonstration that beta-receptor agonists can stimulate bone resorption in organ culture. Bone Miner 23:301-315.
14. Pasco JA, Henry MJ, Sanders KM, Kotowicz MA, Seeman E, Nicholson GC. 2004. β-Adrenergic blockers reduce the risk of fracture partly by increasing bone mineral density: Geelong Osteoporosis Study. J Bone Miner Res 19:19-24.
15. Pennisi P, Signorelli SS, Riccobene S, Celotta G, Di Pino L, La Malfa T, Fiore CE. 2004. Low bone density and abnormal bone turnover in patients with atherosclerosis of peripheral vessels. Osteoporos Int 15:389-395.
16. Prestwood KM, Pilbeam CC, Burleson JA, Woodiel FN, Delmas PD, Deftos LJ, Raisz LG. 1994. The short-term effects of conjugated estrogen on bone turnover in older women. J Clin Endocrinol Metab 79:366-371.
17. Reeve J, Meunier PJ, Parsons JA, Bernat M, Bijvoet OL, Courpron P, Edouard C, Klenerman L, Neer RM, Renier JC, Slovik D, Vismans FJ, Potts Jr JT. 1980. Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: A multicentre trial. Br Med J 280:1340-1344.
18. Reid IR, Ames R, Evans MC, Sharpe S, Gamble G, France JT, Lim TM, Cundy TF. 1992. Determinants of total body and regional bone mineral density in normal postmenopausal women - a key role for fat mass. J Clin Endocrinol Metab 75:45-51.
19. Reid IR, Gamble GD, Grey AB, Black DM, Ensrud KE, Browner WS, Bauer DC. 2005. Beta-blocker use, BMD and fractures in the Study of Osteoporotic Fractures. J Bone Miner Res 20:613-618.
20. Riggs BL, Wahner HW, Melton 3rd LJ, Richelson LS, Judd HL, Offord KP. 1986. Rates of bone loss in the appendicular and axial skeletons of women. Evidence of substantial vertebral bone loss before menopause. J Clin Invest 77:1487-1491.
21. Schlienger RG, Kraenzlin ME, Jick SS, Meier CR. 2004. Use of β-blockers and risk of fractures. JAMA 292:1326-1332.
22. Takeda S, Elefteriou F, Levasseur R, Liu X, Zhao L, Parker KL, Armstrong D, Ducy P, Karsenty G. 2002. Leptin regulates bone formation via the sympathetic nervous system. Cell 111:305-317.
23. Togari A. 2002. Adrenergic regulation of bone metabolism: Possible involvement of sympathetic innervation of osteoblastic and osteoclastic cells. Microsc Res Tech 58:77-84.
24. Uebelhart D, Schlemmer A, Johansen JS, Gineyts E, Christiansen C, Delmas PD. 1991. Effect of menopause and hormone replacement therapy on the urinary excretion of pyridinium cross-links. J Clin Endocrinol Metab 72:367-373.